EDMA

EDMA
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	CA: Schedule III; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methylpropan-2-amine;
CAS Number	133787-66-3 ;
PubChem CID	24257269;
ChemSpider	23553090 ;
UNII	UJ7UU2C6E6;
CompTox Dashboard (EPA)	DTXSID501027143 ;
Chemical and physical data
Formula	C12H17NO2
Molar mass	207.273 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(Cc1ccc2c(c1)OCCO2)NC;
	InChI InChI=1S/C12H17NO2/c1-9(13-2)7-10-3-4-11-12(8-10)15-6-5-14-11/h3-4,8-9,13H,5-7H2,1-2H3 ; Key:UJKWLAZYSLJTKA-UHFFFAOYSA-N ;
	(verify)

3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is an entactogen drug of the methamphetamine class.^[1]^[2] It is an analogue of MDMA where the methylenedioxy ring has been replaced by an ethylenedioxy ring.^[1]^[2] EDMA was first synthesized by Alexander Shulgin.^[1] In his book PiHKAL, the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours.^[1] According to Shulgin, EDMA produces a bare threshold consisting of paresthesia, nystagmus, and hypnogogic imagery, with few to no other effects.^[1] Scientific research has demonstrated that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency relative to MDMA, and with negligible effects on dopamine release.^[2]

References